重度乙型地中海貧血(兒科)
經由藥物誘導體內胎兒血紅蛋白的合成
羥基脲(Hydrea)療法
Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (開啟新視窗)
出處: J Pediatr Hematol Oncol 2011;33(5):339-43.
檢索: PubMed 21602718
DOI碼: 10.1097/MPH.0b013e31821b0770
Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (開啟新視窗)
出處: J Pediatr Hematol Oncol 2013;35(4):e153-6.
檢索: PubMed 23389500
DOI碼: 10.1097/MPH.0b013e31827e8662
Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (開啟新視窗)
出處: J Pediatr Hematol Oncol 2007;29(11):743-6.
檢索: PubMed 17984691
DOI碼: 10.1097/MPH.0b013e318157fd75
Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (開啟新視窗)
出處: Blood 2003;102(4):1529-30.
檢索: PubMed 12702505
DOI碼: 10.1182/blood-2003-01-0117
Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (開啟新視窗)
出處: Transfusion 2007;47(10):1830-6.
檢索: PubMed 17880608
DOI碼: 10.1111/j.1537-2995.2007.01399.x
Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (開啟新視窗)
出處: Iran J Blood Cancer 2009;1(4):147-50.
檢索: IMEMR 107228
https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (開啟新視窗)
Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (開啟新視窗)
出處: Int J Hematol 2012;95(1):51-6.
檢索: PubMed 22180324
DOI碼: 10.1007/s12185-011-0985-6
Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (開啟新視窗)
出處: Pediatr Ann 2008;37(5):339-46.
檢索: PubMed 18543545
A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (開啟新視窗)
出處: Sci Rep. 2022;12(1):2752.
檢索: PubMed 35177777
DOI碼: 10.1038/s41598-022-06774-8
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (開啟新視窗)
出處: Haematologica 2004;89(10):1172-8.
檢索: PubMed 15477200
Hydroxyurea therapy in 49 patients with major beta-thalassemia. (開啟新視窗)
出處: Arch Iran Med 2009;12(3):295-7.
檢索: PubMed 19400608
基因重組紅血球生成素(單獨給予或合併其他製劑)
Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (開啟新視窗)
出處: J Pediatr Hematol Oncol 2002;24(9):777-8.
檢索: PubMed 12468925
Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (開啟新視窗)
出處: Pediatr Hematol Oncol 1997;14(3):285-7.
檢索: PubMed 9185215
其他製劑
Fetal globin gene inducers: novel agents and new potential. (開啟新視窗)
出處: Ann N Y Acad Sci 2010;1202:158-64.
檢索: PubMed 20712788
DOI碼: 10.1111/j.1749-6632.2010.05593.x